NCT04071717 is a NA clinical trial of NIRS neurofeedback in Obesity, sponsored by Wu Wenjun-1.

Who is sponsoring NCT04071717?

NCT04071717 is sponsored by Wu Wenjun-1.

What drugs are being tested in NCT04071717?

Interventions in NCT04071717: NIRS neurofeedback, Sham NIRS neurofeedback.

What condition does NCT04071717 study?

NCT04071717 studies Obesity, Neurofeedback.

Is NCT04071717 still recruiting?

NCT04071717 is currently status unknown. Last updated 28 August 2019.

Last reviewed 2019-08-28 · How we verify

NCT04071717

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-time NIRS Neurofeedback Regulating Brain Cognitive Function in Obese Individuals

Status unknown NA Last updated 28 August 2019

What this trial tests

NA trial testing NIRS neurofeedback in Obesity in 90 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Wu Wenjun-1
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 January 2019
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

NIRS neurofeedback
Sham NIRS neurofeedback

Conditions studied

Obesity — all drugs for Obesity →
Neurofeedback — all drugs for Neurofeedback →

Sponsor

Wu Wenjun-1

Who can join

Adults 18 to 65, any sex, with Obesity or Neurofeedback. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the efficacy of real-time fNIRS neurofeedback for regulating the brain cognitive function in obese individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of NIRS neurofeedback

Trials testing the same drug.

NCT04065906 — Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder · NA · unknown

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04071717 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wu Wenjun-1
Last refreshed: 28 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04071717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing